Status:
COMPLETED
A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Lupus
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
A Study to Determine the Drug Level Profile of Different formulations of BMS-986165 Tablets
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Patients must be willing and able to complete all study-specific procedures and visits
- Healthy patients, as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram, and clinical laboratory determinations
- Body mass index (BMI) of 18 to 32 kg/m2, inclusive, at screening
- Normal renal function at screening
Exclusion
- History or presence of chronic bacterial, viral infection, or autoimmune disorder
- Active TB requiring treatment or documented latent TB within the previous 3 years
- Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption
- WOCBP (women of childbearing potential) must have negative serum or urine pregnancy test.
Key Trial Info
Start Date :
August 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2019
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04065932
Start Date
August 22 2019
End Date
December 10 2019
Last Update
January 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Sciences
Nottingham, United Kingdom, NG11 6JS